Skip to main content
S&P 5007,353.73-4.36%DOW51,523.06-3.44%NASDAQ24,315.00-5.52%BTC$76,146.00-5.78%ETH$2,238.88-7.96%GOLD$4,074.90-0.94%OIL$91.08+0.62%
Smart Investors Daily
SID Premium
OG

NYSE · OGN

Organon & Co.

Healthcare · Drug Manufacturers - General

$13.79

Down-$0.04 (-0.29%)

Updated Nov 6, 2026, 2:11 AM

SID Score

5.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.91B
P/E ratio
3.82
Dividend yield
2.47%
52-week range
$5.69 – $13.85
Volume
3.76M
Avg. volume
5.64M

Price performance · OGN

OGN price history

1M range · 0 trading sessions · Daily adjusted prices

OGN does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest OGN news

The latest Smart Investors Daily articles mentioning OGN.

Stock researchCompany · Overview

OGN research

Overview

Company profile and research snapshot.

Company profile

Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.25
Implied upside
—
Analysts
—
OGN recent ratings
DateFirmRatingTarget
Apr 29, 2026BNP ParibasNeutral—
Apr 28, 2026Piper SandlerNeutral—
Feb 24, 2026BarclaysUnderweight—
Dec 9, 2025BarclaysUnderweight—
Nov 11, 2025JP MorganUnderweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 1, 2026

Organon (OGN) Q3 Results Highlight A Thin Margin Cushion

Organon stock barely budged after Q3 2026 earnings, inching up just 0.2% to US$13.84, yet the fresh numbers tell a more charged story than the muted tape suggests. The latest quarter delivered basic earnings per share of US$0.62 on US$1.57b in revenue, with US$164m in net income. That snapshot matters, but the bigger question for you as a shareholder is how those profits stack up against a thinner 3.5% trailing net margin and weak interest coverage that still hang over the long term...

Yahoo · Oct 30, 2026

Organon (OGN) Q3 Earnings and Revenues Top Estimates

Organon (OGN) delivered earnings and revenue surprises of +3.30% and +0.43%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo · Oct 30, 2026

Organon: Q3 Earnings Snapshot

(OGN) on Friday reported third-quarter earnings of $164 million.The Jersey City, New Jersey-based company said it had profit of 60 cents per share.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By